These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11325319)

  • 1. Chemical andropause and amyloid-beta peptide.
    Gandy S; Almeida OP; Fonte J; Lim D; Waterrus A; Spry N; Flicker L; Martins RN
    JAMA; 2001 May; 285(17):2195-6. PubMed ID: 11325319
    [No Abstract]   [Full Text] [Related]  

  • 2. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 3. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 5. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare reimbursement and prescribing hormone therapy for prostate cancer.
    Keating NL
    J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579
    [No Abstract]   [Full Text] [Related]  

  • 8. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 9. The changing face of hormonal therapy for prostate cancer.
    Seruga B; Tannock IF
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii79-85. PubMed ID: 18790984
    [No Abstract]   [Full Text] [Related]  

  • 10. Principles of endocrine manipulation in the treatment of prostatic cancer.
    Neumann F
    Prog Clin Biol Res; 1985; 185A():73-98. PubMed ID: 3898136
    [No Abstract]   [Full Text] [Related]  

  • 11. The androgen receptor for the radiation oncologist.
    Quero L; Rozet F; Beuzeboc P; Hennequin C
    Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evolution of endocrine therapy for prostate cancer].
    Igawa T; Saito Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():176-81. PubMed ID: 11022709
    [No Abstract]   [Full Text] [Related]  

  • 13. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
    Unger PD; Wang Q; Gordon RE; Stock R; Stone N
    Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 15. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K; Berger M; Ball R
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract]   [Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 19. Should we follow-up serum testosterone in patients with advanced prostate cancer?
    Perachino M
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1031-5. PubMed ID: 20645692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.